Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
Postoperative pain therapeutics are used to support pain-relieving, postoperative suffering, alleviating physiologic, and psychological effects associated with acute pain. It aims to boost recovery and facilitate better functioning of a patient. These therapeutics can be oral, topical, or injectable and may include drugs like opioids, NSAIDS, or Cox-2 inhibitors. Postoperative pain management generally varies from patient to patient, depending upon the severity and the right combination of treatments.
Rising Number of Surgeries Driving Market Growth
The market growth is fuelled by the rising number of surgical procedures, leading to a high demand for postoperative therapeutics. Pharmaceutical companies are working on bringing non-opioid alternatives for pain relief to patients while reducing reliance on opioids. For instance, in July 2024, Heron Therapeutics, Inc., a commercial-stage biotechnology company announced that ZYNRELEF (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") as a qualifying product effective April 1, 2025. The drug has been recognised as a non-opioid and its effectiveness in pain management has been analysed. It has been included in the non-opioid policy where its use is encouraged for postoperative pain management.
Rising Awareness Against Opioids Harnessing Research Studies
The market is experiencing rising awareness of risks and side effects associated with the use of opioids due to which there is a significant rise in research activities in the market. These research studies are focused on exploring non-opioids and their effectiveness in postoperative pain management in varied medical conditions. They play a vital role in clearance of the new therapeutics. For instance, in July 2024, Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company developing novel, non-opioid pain therapeutics, announced the results of a multicenter, randomized clinical trial evaluating vocacapsaicin. The results of the successful clinical trial highlighted a substantial reduction in pain and opioid use for at least one week after bunionectomy with a single dose of vocacapsaicin.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Drug Innovation by Market Players
The market is witnessing the active involvement of market players such as major biotechnology companies in research studies to explore potent drug candidates suitable for post-surgical pain management. The clinical studies are poised to bring new treatment options into the market, bolstering market growth, and simultaneously increasing the availability of appropriate pain relief therapeutics.
For instance, in June 2024, Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced plans to proceed to a Phase 2b registration trial of its lead investigational product ATX101. It combines a biopolymer with an established and verified intracellular sodium ion channel blocker, bupivacaine, to offer weeks of pain relief after total knee arthroplasty (TKA, or replacement), a routine orthopedic procedure. The clinical trial is poised to be backed by strong foundational clinical data from prior exploratory dose-ranging studies. The Phase 2b registration trial is expected to support a new drug application (NDA) filed with the FDA if the clinical trial is successful.
Increasing Regulatory Approvals to Meet Rising Postoperative Pain Therapeutics Market Demand
The market is witnessing an increase in the number of approvals by regulatory authorities such as the FDA, bolstering market development. For instance, in October 2023, a non-opioid combination therapy, Combogesic® IV (known as Maxigesic® IV outside the US), developed by Hyloris Pharmaceuticals was approved by the FDA. It is an intravenous (IV) formulation of acetaminophen and ibuprofen for the treatment of postoperative pain.
Growing Preference for Non-Opioid Alternatives
Opioids have been a leading drug class in postoperative pain treatment, however, the growing concerns regarding the addictive nature of opioids have drawn substantial attention to the development of non-opioid alternatives.
Rising Focus on Non-Pharmacological Therapies
Apart from systemic pharmacological therapies, which commonly include medications like opioids, NSAIDs and/or acetaminophen, IV ketamine, IV lidocaine, steroids, gabapentin, or pregabalin, there has been ample emphasis on developing non-pharmacological therapies as well. Some of the prime examples of pain control include cognitive modalities or mechanical modalities such as transcutaneous electrical nerve stimulation (TENS).
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Market Share by Route of Administration Led by Oral Route
The segmentation by route of administration includes topical, oral, injectable, and others. The oral route of administration is expected to lead the market share due to its convenience, ease of use, and patient preference. Oral therapeutics such as NSAIDs and opioids are commonly prescribed after surgery as they are widely available and can be self-administered. By offering systematic pain relief and being cost-effective, oral medications make a popular choice among healthcare providers and patients. These benefits are the major factors solidifying the preference for oral medications in the market.
The United States dominates the market share driven by the increasing prevalence of chronic diseases and rising incidence of surgeries, driving the demand for postoperative pain therapeutics in the region. There has been a key focus on offering quality postoperative care to patients with the help of developing several novel techniques. The regional dominance is driven by the technologically advanced healthcare infrastructure and the easy availability of postoperative therapeutics and advanced pharmaceuticals. Additionally, strong support from government health initiatives and the presence of leading pharmaceutical companies in the region, contribute to the dominance. The high healthcare expenditure and well-established reimbursement policies further drive the growth of the market in the United States.
Additionally, EU-4 and the United Kingdom follow closely and account for a significant share of the market. Apart from prominent government healthcare services, the region is witnessing growth due to continuous research and development activities conducted by influential healthcare companies and research institutions present in the region. In addition, the presence of a substantial geriatric population also impacts the market demand.
The key features of the market report comprise patent analysis, clinical trials analysis, grant analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Founded in 1849 and headquartered in New York City, Pfizer is a leading biopharmaceutical company. It is renowned for its extensive portfolio in the pharmaceutical market, offering treatments for various medical fields, including oncology, vaccines, internal medicine, and rare diseases, with a strong focus on innovative research.
Bayer AG
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer is a global pharmaceutical and life sciences company. Its product portfolio includes prescription pharmaceuticals, consumer health products, and crop protection solutions, with a focus on innovations in cardiovascular, oncology, and women's health.
Johnson & Johnson
Headquartered in New Jersey, USA, Johnson & Johnson is a multinational pharmaceutical, biotechnology, and medical technologies conglomerate specialising in surgical instruments and technologies.
Heron Therapeutics, Inc.
Established in 1983, and headquartered in San Diego, California, Heron Therapeutics is a global leading biotechnology company specialising in drug development associated with acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034.
Teva Pharmaceuticals USA, Inc.
Established in 1901, and headquartered in Israel, Teva Pharmaceuticals is a global leader in generic medicines and specialty pharmaceuticals, offering a wide portfolio of pain management solutions, including postoperative pain therapeutics. The company focuses on developing and delivering high-quality, affordable treatments to enhance patient care worldwide.
Other key players in the market include Haleon plc (GSK), McKesson Corporation, Pacira Pharmaceuticals, Inc., Cali Biosciences Co., Ltd., and Alembic Pharmaceuticals Ltd.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
The market attained a value of about USD 38.50 billion in 2023, driven by the rising incidence of surgical procedures across the globe.
The market is anticipated to grow at a CAGR of 5.79% during the forecast period of 2024-2032, likely to reach a market value of USD 63.89 billion by 2032.
The market demand is driven by the growing incidence and seriousness of postoperative pain, high chronic disease rate, introduction of advantageous drugs, and the increasing surgical procedures.
Major market trend involves the application of non-opiod therapies for pain treatment. In October 2023, the FDA granted its approval for a non-opioid combination therapy called Combogesic® IV, developed by Hyloris Pharmaceuticals. It is a formulation of acetaminophen and ibuprofen.
Based on drug classes, it includes opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and acyclooxygenase-2-selective inhibitors (COX-2) inhibitors, among others.
The route of administration can be injectable, oral, and topical, among others.
Major distribution channels include hospital pharmacies, retail pharmacies and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Teva Pharmaceutical Industries, Novartis AG, Allergan, Mylan N.V, Pfizer, Purdue Pharma, Janssen Pharmaceuticals, Endo International, Pacira Pharmaceuticals, Egalet Corporation, GlaxoSmithKline Plc., Camurus AB, Pacira BioScience, GlaxoSmithKline Plc., and Trevena.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Route of Administration |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124